Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial

Arturo Chang-Monteagudo, View ORCID ProfileRolando Ochoa-Azze, Yanet Climent-Ruiz, View ORCID ProfileConsuelo Macías-Abraham, Laura Rodríguez-Noda, View ORCID ProfileCarmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Raúl González-Mugica, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María de los A. García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Rodríguez-Prieto, Rinaldo Puga-Gómez, Pedro Pablo Guerra-Chaviano, Yaíma Zúñiga-Rosales, Beatriz Marcheco-Teruel, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Delia Porto-González, Kalet Leon-Monzon, Guan-Wu Chen, Luis Herrera Martinez, View ORCID ProfileYury Valdés-Balbín, View ORCID ProfileDagmar García-Rivera, View ORCID ProfileVicente Vérez-Bencomo, The Soberana 01B Clinical Trial team
doi: https://doi.org/10.1101/2021.02.22.21252091
Arturo Chang-Monteagudo
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolando Ochoa-Azze
2Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rolando Ochoa-Azze
Yanet Climent-Ruiz
2Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Consuelo Macías-Abraham
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Consuelo Macías-Abraham
Laura Rodríguez-Noda
2Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Valenzuela-Silva
3Center of Molecular Immunology, P.O. Box 16040, 216 St. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carmen Valenzuela-Silva
Belinda Sánchez-Ramírez
3Center of Molecular Immunology, P.O. Box 16040, 216 St. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rocmira Perez-Nicado
2Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raúl González-Mugica
2Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tays Hernández-García
3Center of Molecular Immunology, P.O. Box 16040, 216 St. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivette Orosa-Vázquez
3Center of Molecular Immunology, P.O. Box 16040, 216 St. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianniz Díaz-Hernández
3Center of Molecular Immunology, P.O. Box 16040, 216 St. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María de los A. García-García
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanet Jerez-Barceló
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yenisey Triana-Marrero
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Ruiz-Villegas
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Rodríguez-Prieto
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rinaldo Puga-Gómez
4Cira Garcia Clinic, Calle 20 NO. 4101 esq. a Av. 41 Miramar, La Habana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Pablo Guerra-Chaviano
5National Center for Coordination of Clinical Trial (CENCEC) Calle 5ta A e/ 60 y 62 Miramar, Playa, CP 11300, La Habana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaíma Zúñiga-Rosales
6National Center of Medical Genetics, Ave. 31 Esq.146 No 3102, Reparto Cubanacán CP. 11400
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beatriz Marcheco-Teruel
6National Center of Medical Genetics, Ave. 31 Esq.146 No 3102, Reparto Cubanacán CP. 11400
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mireida Rodríguez-Acosta
7National Civil Defense Research Laboratory, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Noa-Romero
7National Civil Defense Research Laboratory, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet Enríquez-Puertas
7National Civil Defense Research Laboratory, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delia Porto-González
8National Blood Program, Ministry of Health, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kalet Leon-Monzon
3Center of Molecular Immunology, P.O. Box 16040, 216 St. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guan-Wu Chen
9Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Herrera Martinez
10Biocubafarma, Ave. Independencia #8126, esq. a Calle 100. Boyeros. La Habana. Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yury Valdés-Balbín
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yury Valdés-Balbín
Dagmar García-Rivera
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dagmar García-Rivera
Vicente Vérez-Bencomo
1Institute of Hematology and Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vicente Vérez-Bencomo
  • For correspondence: vicente.verez@finlay.edu.cu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excellent safety profile one month after vaccination for all participants, similar to that previously found during vaccination of naïve individuals; b) a single dose of vaccine induces a >20 fold increase in antibody response one week after vaccination and remarkably 4-fold higher virus neutralization compared to the median obtained for Cuban convalescent serum panel. These preliminary results prompt initiation of a phase II trial in order to establish a general vaccination protocol for convalescents.

Competing Interest Statement

Finlay Vaccine Institute and Center for Molecular Immunology has filed patent applications relating to use vaccination in individuals with preexisting immunity SARS-CoV-2

Clinical Trial

IFV/COR/07 RPCE00000349

Clinical Protocols

https://rpcec.sld.cu/trials/RPCEC00000349

Funding Statement

This work was partially funded by Fondo de Ciencia e Innovacion (FONCI) from the Ministry of Science and Enviroment of Cuba (Project-2020-20)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Independent Ethical Committee for the Study of Human Subjects in the Institute of Hematology and Immunology

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will b e available at https://rpcec.sld.cu/trials/RPCEC00000349 or under request to author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 03, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial
Arturo Chang-Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Consuelo Macías-Abraham, Laura Rodríguez-Noda, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Raúl González-Mugica, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María de los A. García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Rodríguez-Prieto, Rinaldo Puga-Gómez, Pedro Pablo Guerra-Chaviano, Yaíma Zúñiga-Rosales, Beatriz Marcheco-Teruel, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Delia Porto-González, Kalet Leon-Monzon, Guan-Wu Chen, Luis Herrera Martinez, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Vérez-Bencomo, The Soberana 01B Clinical Trial team
medRxiv 2021.02.22.21252091; doi: https://doi.org/10.1101/2021.02.22.21252091
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial
Arturo Chang-Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Consuelo Macías-Abraham, Laura Rodríguez-Noda, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Raúl González-Mugica, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María de los A. García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Rodríguez-Prieto, Rinaldo Puga-Gómez, Pedro Pablo Guerra-Chaviano, Yaíma Zúñiga-Rosales, Beatriz Marcheco-Teruel, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Delia Porto-González, Kalet Leon-Monzon, Guan-Wu Chen, Luis Herrera Martinez, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Vérez-Bencomo, The Soberana 01B Clinical Trial team
medRxiv 2021.02.22.21252091; doi: https://doi.org/10.1101/2021.02.22.21252091

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (195)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5674)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (863)
  • Geriatric Medicine (88)
  • Health Economics (230)
  • Health Informatics (761)
  • Health Policy (390)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6467)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (846)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (162)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (963)
  • Public and Global Health (2224)
  • Radiology and Imaging (376)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)